Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The current state of recombinant allergens for immunotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Highlights in allergic contact dermatitis 2018/2019

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The impact of common metal allergens in daily devices

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Allergen-specific immunotherapy and risk of autoimmune disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical update on contact allergy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Subcutaneous immunotherapy is a well documented treatment of allergic rhinitis and asthma. The majority of the disadvantages of the treatment are related to the poor quality of the natural allergen extracts which can contain varying amounts of individual allergens including allergens to which the patient may not be sensitized. Recombinant allergens offer a possibility to use well defined molecules with consistent pharmaceutical quality defined in mass units. The proof of concept of the clinical efficacy of recombinant allergens is based on two studies published as full articles.
OriginalsprogEngelsk
TidsskriftCurrent Opinion in Allergy and Clinical Immunology
Vol/bind10
Udgave nummer6
Sider (fra-til)575-81
Antal sider7
ISSN1528-4050
DOI
StatusUdgivet - 1 dec. 2010

ID: 32167064